HCG - HealthCare Global Enterprises Limited Share Price

Management's outlook for HealthCare Global Enterprises Limited (HCG) indicates a commitment to steady growth, targeting an annual revenue increase of over 15%. Significant growth is anticipated through existing centers, with existing hospital capacities reportedly achieving only 60% of their revenue potential. They plan a combination of brownfield expansions in high-potential markets and calibrated greenfield additions to support this growth trajectory.

Key forward-looking points include:

1. Financial Performance: For Q3 FY26, HCG reported revenues of INR 633 crore, reflecting a 13.4% year-on-year growth, driven by an 8% increase in patient volume. Year-to-date revenue reached INR 1,893 crore, a 16% increase.

2. Adjusted EBITDA: The adjusted EBITDA for Q3 FY26 was INR 111 crore, showcasing a 20% year-on-year growth, with margins improving from 16.5% to 17.5%.

3. Facility Expansions: The North Bangalore facility, set to launch in Q4 FY26, will add over 120 beds and is expected to enhance competitive positioning by offering advanced MR-LINAC technology.

4. Clinical Excellence: HCG highlighted advancements such as achieving complete responses in challenging cancer cases and accreditation for its ethics committee, underscoring its commitment to quality care.

5. Digital Revenue Growth: Digital revenues grew 26% year-on-year, with improved efficiency in campaign management leading to increased share from 20% to 27%.

6. Return on Capital: The pre-tax ROCE stood at 13.3% for the first nine months of FY26, with expectations for further increases as the organization scales its operations.

7. Marginal Gains: Management indicated aspirations for EBITDA margins to improve to the mid-20% range over the next few years, with a focus on operating leverage as utilization increases.

In summary, HCG is strategically positioned for sustainable growth, leveraging existing infrastructure and clinical capabilities while expanding into new markets.

Question 1: "When I add all of this, I see that there is a potential to grow at probably about 22% - 25% annually for the next three - four years. So, when you are guiding 15%+ growth, is it that we are a bit conservative over here?"

Answer 1: "Thank you for the question. Our ambition is, of course, to grow higher than the 15% we've committed to. However, historical trends and competitive pressures suggest that growth will occur in phases, and prices in cancer care are sensitive. While 15%+ is achievable, our aspiration is indeed to exceed this guidance when possible."

Question 2: "Would you say that in the long term, the potential to reach mid-25% is there?"

Answer 2: "Certainly. We believe that our current trajectory, with margins trending upwards from 17.5% to about 18.5%, can eventually lead us to target 23% to 24% over the next three to four years. Mature centers have already demonstrated this potential."

Question 3: "Could you delve a bit into what factors led to slower growth in the Southern cluster during Q3FY26?"

Answer 3: "The Southern cluster's growth was impacted by a strike that lasted around 20-25 days, particularly affecting our Vizag market. This disruption slowed down volumes temporarily, but our Bangalore cluster performed well. We anticipate volume growth of about 10% in subsequent quarters as operations normalize."

Question 4: "What percentage of your revenues is coming from patients who have probably had the first line of treatment or first treatment in some multi-specialty hospitals?"

Answer 4: "Approximately 45% of our patients come to us after seeking treatment at a multi-specialty hospital. We want to focus more on attracting first opinions as we expand our reach and enhance our patient base in the future."

Question 5: "What would be the expected capex for FY '27 and '28?"

Answer 5: "For FY '26, our capex is expected to be around INR 275 crore - INR 280 crore, with an anticipated increase of about 10-12% for FY '27. This reflects our commitment to strategic expansion investments."